Building the Next Pipeline of Specialty APIs
The demand for specialised pharmaceutical ingredients is growing across orphan, ultra-rare and niche therapeutic categories, creating new opportunities for focused API development.
Strategic Partnership for Specialty APIs
HRV Pharma has entered into a multi-year strategic partnership with Haleos Labs to accelerate the development and GMP manufacturing of specialty APIs for regulated and semi-regulated markets.
Combining Manufacturing and Global Market Access
The collaboration brings together Haleos Labs’ manufacturing and specialty API capabilities with HRV Pharma’s global market access and regulatory execution. The partnership is expected to develop 5 to 7 new molecules each year, spanning areas including rare diseases, CNS disorders and metabolic conditions.
Building a Broader Pipeline of High-Value APIs
By combining development, regulatory and manufacturing capabilities, the partnership aims to build a broader pipeline of high-value APIs for underserved therapeutic segments globally.
Featured in The Times of India
